AstraZeneca shares rally to new highs

The pharmaceutical giant's shares have been on a tear in recent months, reaching a new all-time high of 14,255 EUR on Thursday.

The rally has been driven by a number of factors, including strong sales of its cancer drugs and positive news about its COVID-19 vaccine.

AstraZeneca's shares have been a hot commodity in 2024, with investors betting on the company's continued success in the pharmaceutical industry. The company's shares have risen by more than 25% since the beginning of the year, outperforming the broader market.

One of the key drivers of AstraZeneca's share price rally has been the strong sales of its cancer drugs. The company's blockbuster cancer drug, Tagrisso, has been a major success, and AstraZeneca has a number of other promising cancer drugs in its pipeline.

Another factor that has helped to boost AstraZeneca's share price is the positive news about its COVID-19 vaccine. The company's vaccine, which was developed in partnership with Oxford University, has been shown to be safe and effective in clinical trials.

AstraZeneca's shares are currently trading at around 14,255 EUR, which is close to their all-time high. The company's strong fundamentals and positive outlook make it a good investment for investors who are looking for growth potential.